[go: up one dir, main page]

EE04991B1 - Osake, ravimvorm, nende valmistamismeetodid, osakeste kasutamine ning farmatseutiline pakend - Google Patents

Osake, ravimvorm, nende valmistamismeetodid, osakeste kasutamine ning farmatseutiline pakend

Info

Publication number
EE04991B1
EE04991B1 EEP200200151A EEP200200151A EE04991B1 EE 04991 B1 EE04991 B1 EE 04991B1 EE P200200151 A EEP200200151 A EE P200200151A EE P200200151 A EEP200200151 A EE P200200151A EE 04991 B1 EE04991 B1 EE 04991B1
Authority
EE
Estonia
Prior art keywords
pharmaceutical
particle
particles
preparation
methods
Prior art date
Application number
EEP200200151A
Other languages
English (en)
Inventor
Verreck Geert
Elvire Colette Baert Lieven
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of EE200200151A publication Critical patent/EE200200151A/et
Publication of EE04991B1 publication Critical patent/EE04991B1/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
EEP200200151A 1999-09-24 2000-08-31 Osake, ravimvorm, nende valmistamismeetodid, osakeste kasutamine ning farmatseutiline pakend EE04991B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99203128 1999-09-24
PCT/EP2000/008522 WO2001022938A1 (en) 1999-09-24 2000-08-31 Antiviral compositions

Publications (2)

Publication Number Publication Date
EE200200151A EE200200151A (et) 2003-04-15
EE04991B1 true EE04991B1 (et) 2008-04-15

Family

ID=8240674

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200151A EE04991B1 (et) 1999-09-24 2000-08-31 Osake, ravimvorm, nende valmistamismeetodid, osakeste kasutamine ning farmatseutiline pakend

Country Status (35)

Country Link
US (4) US7241458B1 (et)
EP (1) EP1225874B1 (et)
JP (1) JP4919566B2 (et)
KR (2) KR100785360B1 (et)
CN (1) CN1234347C (et)
AP (1) AP1639A (et)
AT (1) ATE316781T1 (et)
AU (2) AU775360B2 (et)
BG (1) BG65754B1 (et)
BR (1) BRPI0014271B1 (et)
CA (1) CA2384188C (et)
CY (1) CY1105268T1 (et)
CZ (1) CZ300712B6 (et)
DE (1) DE60025837T2 (et)
DK (1) DK1225874T3 (et)
EA (1) EA005423B1 (et)
EE (1) EE04991B1 (et)
ES (1) ES2258018T3 (et)
HK (1) HK1048768B (et)
HR (1) HRP20020247B1 (et)
HU (1) HU228449B1 (et)
IL (1) IL148801A0 (et)
IS (1) IS2567B (et)
MX (1) MXPA02003182A (et)
NO (1) NO333358B1 (et)
NZ (1) NZ517025A (et)
OA (1) OA12029A (et)
PL (1) PL207590B1 (et)
PT (1) PT1225874E (et)
SI (1) SI1225874T1 (et)
SK (1) SK285240B6 (et)
TR (1) TR200200763T2 (et)
UA (1) UA74797C2 (et)
WO (1) WO2001022938A1 (et)
ZA (1) ZA200202289B (et)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE396978T1 (de) 1999-10-07 2008-06-15 Amgen Inc Triazin-kinase-hemmer
EP1175205B1 (en) 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
AU2001237041B9 (en) 2000-02-17 2005-07-28 Amgen Inc. Kinase inhibitors
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
IL157608A0 (en) 2001-02-27 2004-03-28 Teva Pharma New crystal forms of lamotrigine and processes for their preparations
PT1404300E (pt) 2001-06-22 2009-11-09 Bend Res Inc Composições farmacêuticas de dispersões de fármacos e polímeros neutros
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7115617B2 (en) 2001-08-22 2006-10-03 Amgen Inc. Amino-substituted pyrimidinyl derivatives and methods of use
US6939874B2 (en) 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
CA2463989C (en) 2001-10-17 2012-01-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pyrimidine derivatives, pharmaceutical compositions containing these compounds, the use thereof and process for the preparation thereof
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7375222B2 (en) 2002-02-05 2008-05-20 Astellas Pharma Inc. 2,4,6-Triamino-1,3,5-triazine derivative
DE60312670T2 (de) * 2002-04-23 2007-12-06 Teva Pharmaceutical Industries Ltd. Pharmazeutische zusammensetzung enthaltend lamotrigine-partikel mit definierter morphologie
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
US7015227B2 (en) 2002-06-21 2006-03-21 Cgi Pharmaceuticals, Inc. Certain amino-substituted monocycles as kinase modulators
MXPA05001096A (es) 2002-07-29 2005-11-23 Rigel Pharmaceuticals Inc Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
ES2422196T3 (es) 2002-08-09 2013-09-09 Janssen Pharmaceutica Nv Procesos para la preparación de 4-4-4-(2-cianoetenil)-2,6-dimetilfenil)amino)-2-pirimidinil)aminobenzonitrilo
ES2677769T3 (es) * 2002-09-20 2018-08-06 Alpharma Pharmaceuticals Llc Subunidad secuestrante y composiciones y procedimientos relacionados
EA200500721A1 (ru) * 2002-11-28 2005-12-29 Шеринг Акциенгезельшафт Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
AU2002350719A1 (en) 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
CN102558155A (zh) 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
ES2598404T3 (es) * 2003-02-07 2017-01-27 Janssen Pharmaceutica Nv Derivados de pirimidina para la prevención de infección por el VIH
CL2004000303A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
WO2005011702A1 (en) 2003-07-17 2005-02-10 Tibotec Pharmaceuticals Ltd. Process for preparing particles containing an antiviral
AU2004265288A1 (en) 2003-07-30 2005-02-24 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
JP2007510626A (ja) 2003-10-17 2007-04-26 アストラゼネカ アクチボラグ 癌の治療に使用の４−（ピラゾール−３−イルアミノ）ピリミジン誘導体
PL1725540T3 (pl) 2004-03-05 2013-02-28 Hoffmann La Roche Diaminopirymidyny jako antagoniści p2x3 i p2x2/3
CN101084212A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶介导剂的用途
CN101083993A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其作为硬脂酰CoA去饱和酶抑制剂的用途
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
AU2005286793A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-CoA desaturase enzymes
MX2007003325A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores estearoil-coa-desaturasa.
AU2005286648A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US7777036B2 (en) 2004-09-20 2010-08-17 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
US7557207B2 (en) 2004-11-24 2009-07-07 Rigel Pharmaceuticals, Inc. Spiro 2,4-pyrimidinediamine compounds and their uses
CN101115761B (zh) 2005-01-19 2012-07-18 里格尔药品股份有限公司 2,4-嘧啶二胺化合物的前药及其应用
BRPI0607455A2 (pt) 2005-02-16 2009-09-01 Astrazeneca Ab composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
CN101119976B (zh) * 2005-02-18 2010-12-22 泰博特克药品有限公司 抑制hiv的2-(4-氰基苯氨基)嘧啶氧化物衍生物
DE602006015291D1 (de) * 2005-03-04 2010-08-19 Little Island Co Cork Hiv-inhibierende 2-(4-cyanophenyl)-6-hydroxylaminopyrimidine
TW200710091A (en) 2005-04-11 2007-03-16 Tibotec Pharm Ltd (1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
JP2008540622A (ja) 2005-05-16 2008-11-20 アストラゼネカ アクチボラグ 化合物
CN101248051B (zh) * 2005-05-26 2013-07-17 泰博特克药品有限公司 制备4-[(1,6-二氢-6-氧代-2-嘧啶基)氨基]苯基氰的方法
BRPI0611187A2 (pt) 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
ES2562056T3 (es) 2005-09-01 2016-03-02 F. Hoffmann-La Roche Ag Diaminopirimidinas como moduladores P2X3 y P2X2/3
WO2007025899A1 (en) 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
EP1924565B1 (en) 2005-09-01 2016-09-14 F.Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p3x2/3 modulators
EP1945631B8 (en) 2005-10-28 2013-01-02 AstraZeneca AB 4- (3-aminopyrazole) pyrimidine derivatives for use as tyrosine kinase inhibitors in the treatment of cancer
WO2007056205A2 (en) * 2005-11-04 2007-05-18 Eastman Chemical Company Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
SI2029110T1 (sl) * 2006-06-06 2012-01-31 Tibotec Pharm Ltd Z razprševanjem posušeni pripravki TMC125
RU2445077C2 (ru) 2006-06-19 2012-03-20 АЛФАРМА, Инк. Фармацевтические композиции
CA2665726C (en) * 2006-10-11 2016-04-19 Alpharma, Inc. Pharmaceutical compositions
WO2008068299A2 (en) 2006-12-06 2008-06-12 Tibotec Pharmaceuticals Ltd. Hydrobromide salt of an anti-hiv compound
CL2008000746A1 (es) * 2007-03-14 2008-09-22 Tibotec Pharm Ltd Composicion farmaceutica en solucion que comprende tmc278 y un polimero soluble en agua; proceso de preparacion de dicha composicion; y uso de un polvo que comprende tmc278 para tratar sida.
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
EA018377B1 (ru) * 2007-06-08 2013-07-30 Бёрингер Ингельхайм Интернациональ Гмбх Препарат невирапина пролонгированного высвобождения
JP2010531301A (ja) * 2007-06-25 2010-09-24 テイボテク・フアーマシユーチカルズ ダルナビル及びエトラビリンを含んでなる組み合わせ調剤
WO2009051782A1 (en) * 2007-10-18 2009-04-23 Concert Pharmaceuticals Inc. Deuterated etravirine
US7982036B2 (en) * 2007-10-19 2011-07-19 Avila Therapeutics, Inc. 4,6-disubstitued pyrimidines useful as kinase inhibitors
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
EP2224805A4 (en) * 2007-12-17 2013-10-16 Alpharma Pharmaceuticals Llc PHARMACEUTICAL COMPOSITION
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
WO2010022125A1 (en) * 2008-08-20 2010-02-25 Schering Corporation Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2734489C (en) * 2008-08-20 2016-11-08 Southern Research Institute Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
JP2012502906A (ja) * 2008-09-17 2012-02-02 ネクター セラピューティックス オリゴマー−プロテアーゼ阻害剤コンジュゲート
CN101744823B (zh) * 2008-12-17 2013-06-19 广东东阳光药业有限公司 一种二氢嘧啶类化合物的固体分散体及其药用制剂
AU2010230344B9 (en) 2009-03-30 2014-11-27 Janssen Sciences Ireland Uc Co-crystal of etravirine and nicotinamide
AU2010259009A1 (en) * 2009-06-08 2012-01-12 Nantbioscience, Inc. Triazine derivatives and their therapeutical applications
RU2556986C2 (ru) * 2009-06-22 2015-07-20 Эмкьюар Фармасьютикалз Лимитед Способ синтеза диарилпиримидинового ненуклеозидного ингибитора обратной транскриптазы
JP5713367B2 (ja) 2010-06-04 2015-05-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｌｒｒｋ２モジュレーターとしてのアミノピリミジン誘導体
EA201390421A1 (ru) 2010-09-22 2013-09-30 Арена Фармасьютикалз, Инк. Модуляторы рецептора gpr119 и лечение связанных с ним нарушений
BR112013011600B1 (pt) 2010-11-10 2022-01-11 Genentech, Inc Derivados de pirazol aminopirimidina, seu uso e composição que os compreende
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
JP5809379B2 (ja) * 2012-04-11 2015-11-10 ダウ グローバル テクノロジーズ エルエルシー 新規徐放剤形
CN104364329B (zh) * 2012-04-11 2016-08-17 陶氏环球技术有限责任公司 包含有机稀释剂和纤维素醚的组合物
WO2013154981A1 (en) * 2012-04-11 2013-10-17 Dow Global Technologies Llc Melt-extruded composition comprising a cellulose ether
NZ702747A (en) 2012-06-13 2017-03-31 Incyte Holdings Corp Substituted tricyclic compounds as fgfr inhibitors
US9139535B2 (en) 2012-07-12 2015-09-22 Hetero Research Foundation Process for rilpivirine using novel intermediate
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
LT2986610T (lt) 2013-04-19 2018-04-10 Incyte Holdings Corporation Bicikliniai heterociklai, kaip fgfr inhibitoriai
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP4445956A3 (en) 2015-01-06 2024-12-04 Arena Pharmaceuticals, Inc. Compound for use in treating conditions related to the s1p1 receptor
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
SG10201913036RA (en) 2015-02-20 2020-02-27 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
AR100459A1 (es) * 2015-05-15 2016-10-05 Química Luar S R L Una composición farmacéutica antiviral de uso tópico
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
WO2018187652A1 (en) 2017-04-06 2018-10-11 Janssen Pharmaceutica Nv 2,4-diaminopyrimidine derivatives as histamine h4 modulators
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
EP3788046B1 (en) 2018-05-04 2025-12-10 Incyte Corporation Salts of an fgfr inhibitor
EP4309737A3 (en) 2018-05-04 2024-03-27 Incyte Corporation Solid forms of an fgfr inhibitor and processes for preparing the same
CA3102136A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CR20220169A (es) 2019-10-14 2022-10-27 Incyte Corp Heterociclos bicíclicos como inhibidores de fgfr
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4065121A4 (en) 2019-11-29 2023-11-29 Aptorum Therapeutics Limited Composition including rilpivirine and use thereof for treating tumors or cancer
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
KR20220131900A (ko) 2019-12-04 2022-09-29 인사이트 코포레이션 Fgfr 억제제의 유도체
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
KR102145925B1 (ko) 2020-03-03 2020-08-19 협동조합 바이오융합기술 사포닌 성분이 함유된 항 바이러스용 조성물의 제조방법
CN111875548A (zh) * 2020-07-16 2020-11-03 山东大学 一种5位芳环取代的二芳基嘧啶类衍生物及其制备方法与应用
US12065494B2 (en) 2021-04-12 2024-08-20 Incyte Corporation Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
AR126101A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
CN116425683A (zh) * 2023-04-04 2023-07-14 上药康丽（常州）药业有限公司 一种米诺地尔的合成精制方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US230963A (en) 1880-08-10 John kobeetson
US2742466A (en) 1956-04-17 Chx n nhx c c
US2671810A (en) 1952-05-24 1954-03-09 Du Pont Long-chain diketones
US2748124A (en) 1954-05-06 1956-05-29 Searle & Co 1-(4-anilino-2-pyrimidino)-3-alkylureas
SU143808A1 (ru) 1961-02-14 1961-11-30 Н.В. Козлова Способ получени 2-хлор-4,6-ди и 2,4,6-три-(2,4-дихлоранилин)-симм. триазинов
GB1010998A (en) 1962-10-09 1965-11-24 British Petroleum Co Pyrimidine derivatives
US3478030A (en) 1966-06-27 1969-11-11 Abbott Lab Benzamide substituted anilino aminopyrimidines
BE754242A (fr) 1970-07-15 1971-02-01 Geigy Ag J R Diamino-s-triazines et dinitro-s-triazines
DE2038182C3 (de) 1970-07-31 1980-10-09 Ciba-Geigy Ag, Basel (Schweiz) 2-Substituierte 4,6-Diamino-stri azine
GB1483271A (en) 1975-03-22 1977-08-17 Ciba Geigy Ag Pigment complexes
GB1477349A (en) 1975-09-24 1977-06-22 Ciba Geigy Ag Azo pigments
US4096206A (en) 1976-02-09 1978-06-20 Borg-Warner Corporation Flame-retardant triazines
FR2400535A1 (fr) 1977-01-27 1979-03-16 Borg Warner Composition de polymere contenant des tris(haloarylamino)triazines ou des tris(haloarylthio)triazines fournissant une aptitude au retardement d'inflammation
FR2398740A1 (fr) 1978-11-06 1979-02-23 Borg Warner Compose fournissant une aptitude au retardement d'inflammation dans un polymere
JPS57203072A (en) 1981-06-05 1982-12-13 Sankyo Co Ltd 4-anilinopyrimidine derivative, its preparation, antidepressant comprising it as active ingredient
US4659363A (en) 1983-07-25 1987-04-21 Ciba-Geigy Corporation N-(2-nitrophenyl)-2-aminopyrimidine derivatives, the preparation and use thereof
US4652645A (en) 1983-11-16 1987-03-24 Ciba-Geigy Corporation Cationic compounds
EP0172786B1 (de) 1984-06-25 1991-01-30 Ciba-Geigy Ag Pyrimidinderivate wirksam als Schädlingsbekämpfungsmittel
JPH0784445B2 (ja) * 1986-12-03 1995-09-13 クミアイ化学工業株式会社 ピリミジン誘導体および農園芸用殺菌剤
ZA892407B (en) 1988-03-31 1989-11-29 Mitsubishi Chem Ind 6-substituted acyclopyrimidine nucleoside derivative and antiviral agent containing the same as active ingredient thereof
JPH0252360A (ja) 1988-08-15 1990-02-21 Fujitsu Ltd 電子写真感光体
US4980371A (en) 1988-12-21 1990-12-25 Merrell Dow Pharmaceuticals Antiretroviral furan ketones
FI95376C (fi) 1989-03-22 1996-01-25 Ciba Geigy Ag Mikrobisidiset 2-anilino-pyrimidiinijohdannaiset
IE63502B1 (en) 1989-04-21 1995-05-03 Zeneca Ltd Aminopyrimidine derivatives useful for treating cardiovascular disorders
JPH02300264A (ja) 1989-05-16 1990-12-12 Fuji Photo Film Co Ltd アミノピリミジンアゾメチン色素とその製造方法
JPH02308248A (ja) 1989-05-24 1990-12-21 Fuji Photo Film Co Ltd アミノピリミジン系色素形成カプラーおよび該カプラーを含有するハロゲン化銀カラー写真感光材料
US5064963A (en) 1990-04-25 1991-11-12 American Cyanamid Company Process for the synthesis of n-(3-(1h-imidazol-1-yl)phenyl-4-(substituted)-2-pyrimidinamines
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
IE75693B1 (en) 1990-07-10 1997-09-10 Janssen Pharmaceutica Nv HIV-inhibiting benzeneacetamide derivatives
JPH04159381A (ja) 1990-10-23 1992-06-02 Arakawa Chem Ind Co Ltd ロジンエステルの製造方法
EP0541966A3 (en) 1991-11-15 1994-09-07 American Cyanamid Co Process for preparing amide derivatives from halomines and acid halides
US5283274A (en) 1992-06-19 1994-02-01 Uniroyal Chemical Company, Inc. Substituted pyrimidines and substituted triazines as rubber-to-metal adhesion promoters
IL106324A (en) 1992-07-17 1998-09-24 Shell Int Research Transformed pyrimidine compounds, their preparation and use as pesticides
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
WO1994018963A1 (en) 1993-02-22 1994-09-01 Janssen Pharmaceutica N.V. Method of reversing resistance of hiv-1 strains to zidovudine
WO1995010506A1 (en) 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
PL313973A1 (en) 1993-10-12 1996-08-05 Du Pont Merck Pharma 1 n-alkyl-n-arylopyrimidin amines and their derivatives
GB9325217D0 (en) 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
DE19509807A1 (de) * 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
TW530047B (en) 1994-06-08 2003-05-01 Pfizer Corticotropin releasing factor antagonists
IL114208A0 (en) 1994-06-27 1995-10-31 Merck & Co Inc Combinations of compounds pharmaceutical compositions containing them and their use as hiv protease inhibitors
TW401303B (en) 1994-07-01 2000-08-11 Janssen Pharmaceutica Nv Anti-HIV triple combination
US5574040A (en) 1995-01-06 1996-11-12 Picower Institute For Medical Research Pyrimidine compounds and methods of use to derivatize neighboring lysine residues in proteins under physiologic conditions
JP3691101B2 (ja) 1995-01-24 2005-08-31 三洋電機株式会社 有機エレクトロルミネッセンス素子
DE19504832A1 (de) * 1995-02-14 1996-08-22 Basf Ag Feste Wirkstoff-Zubereitungen
US5691364A (en) 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
US5837436A (en) 1995-07-28 1998-11-17 Fuji Photo Film Co., Ltd. Silver halide color photographic material and package thereof
JPH09101590A (ja) 1995-07-28 1997-04-15 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料およびその包装体
JPH0968784A (ja) 1995-08-31 1997-03-11 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料
JPH0980676A (ja) 1995-09-13 1997-03-28 Fuji Photo Film Co Ltd ハロゲン化銀カラー写真感光材料およびその包装体
GB9519197D0 (en) 1995-09-20 1995-11-22 Affinity Chromatography Ltd Novel affinity ligands and their use
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
CN1163401A (zh) 1996-02-13 1997-10-29 李占元 全自动血球计数仪试剂及配制方法
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
EP0872233A1 (en) * 1997-04-14 1998-10-21 Janssen Pharmaceutica N.V. Antiretroviral compositions with improved bioavailability
JPH11116555A (ja) 1997-10-14 1999-04-27 Ube Ind Ltd ４−アニリノピリミジン誘導体及びそれを有効成分とする農園芸用の殺虫・殺ダニ・殺菌剤
US6200977B1 (en) 1998-02-17 2001-03-13 Tularik Inc. Pyrimidine derivatives
ATE232521T1 (de) * 1998-03-27 2003-02-15 Janssen Pharmaceutica Nv Hiv hemmende pyrimidin derivate
DE69943247D1 (de) * 1998-03-27 2011-04-14 Janssen Pharmaceutica Nv HIV hemmende Pyrimidin Derivate
EP0945442A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted pyrimidine derivatives
EP0945447A1 (en) * 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
JP2000111191A (ja) 1998-08-04 2000-04-18 Tokyo Gas Co Ltd 吸収冷温水機
KR100658489B1 (ko) 1998-11-10 2006-12-18 얀센 파마슈티카 엔.브이. Ｈｉｖ 복제를 억제하는 피리미딘
JP4159381B2 (ja) 2003-02-24 2008-10-01 花王株式会社 歯ブラシ
US6876717B1 (en) * 2004-08-19 2005-04-05 Intel Corporation Multi-stage programmable Johnson counter

Also Published As

Publication number Publication date
PT1225874E (pt) 2006-06-30
MXPA02003182A (es) 2002-09-30
ES2258018T3 (es) 2006-08-16
CN1234347C (zh) 2006-01-04
CZ2002907A3 (cs) 2002-05-15
AP1639A (en) 2006-07-24
HRP20020247A2 (en) 2004-04-30
AP2002002482A0 (en) 2002-06-30
EP1225874A1 (en) 2002-07-31
NZ517025A (en) 2003-07-25
KR100820605B1 (ko) 2008-04-08
BG65754B1 (bg) 2009-10-30
US20070196478A1 (en) 2007-08-23
JP2003510264A (ja) 2003-03-18
US20060127487A1 (en) 2006-06-15
EP1225874B1 (en) 2006-02-01
AU2004224973A1 (en) 2004-11-25
CZ300712B6 (cs) 2009-07-22
IS2567B (is) 2009-12-15
US7887845B2 (en) 2011-02-15
ATE316781T1 (de) 2006-02-15
IL148801A0 (en) 2002-09-12
EE200200151A (et) 2003-04-15
IS6256A (is) 2002-01-31
OA12029A (en) 2006-04-28
BR0014271A (pt) 2002-05-21
SK3762002A3 (en) 2002-09-10
CA2384188C (en) 2008-06-17
HRP20020247B1 (hr) 2011-02-28
NO20021443D0 (no) 2002-03-22
NO20021443L (no) 2002-03-22
DE60025837T2 (de) 2006-11-02
NO333358B1 (no) 2013-05-13
HUP0203568A2 (hu) 2003-02-28
UA74797C2 (uk) 2006-02-15
TR200200763T2 (tr) 2003-09-22
KR20020063847A (ko) 2002-08-05
PL207590B1 (pl) 2011-01-31
US7241458B1 (en) 2007-07-10
US20100172970A1 (en) 2010-07-08
PL354026A1 (en) 2003-12-15
AU775360B2 (en) 2004-07-29
AU2004224973C1 (en) 2006-06-01
BRPI0014271B1 (pt) 2021-06-22
SI1225874T1 (sl) 2006-06-30
DK1225874T3 (da) 2006-06-12
HK1048768B (zh) 2006-08-04
EA200200401A1 (ru) 2002-10-31
AU7512700A (en) 2001-04-30
JP4919566B2 (ja) 2012-04-18
EA005423B1 (ru) 2005-02-24
HU228449B1 (en) 2013-03-28
AU2004224973B2 (en) 2005-08-25
HUP0203568A3 (en) 2006-07-28
CY1105268T1 (el) 2010-03-03
WO2001022938A1 (en) 2001-04-05
KR100785360B1 (ko) 2007-12-18
BG106521A (bg) 2002-12-29
CN1376057A (zh) 2002-10-23
DE60025837D1 (de) 2006-04-13
CA2384188A1 (en) 2001-04-05
SK285240B6 (sk) 2006-09-07
ZA200202289B (en) 2003-08-27
HK1048768A1 (en) 2003-04-17
KR20070036805A (ko) 2007-04-03

Similar Documents

Publication Publication Date Title
EE200200151A (et) Osake, ravimvorm, nende valmistamismeetodid, osakeste kasutamine ning farmatseutiline pakend
EE9800304A (et) Osakesed, nende valmistamismeetod ja kasutamine, farmatseutiline doseerimisvorm ja selle valmistamismeetod, tahke dispersioon ning farmatseutiline pakend
FR2805818B1 (fr) Derives d'azetidine, leur preparation et les compositions pharmaceutiques les contenant
AU5936400A (en) Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
HUP0300593A3 (en) Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets
EE04996B1 (et) Reguleeritud vabanemisega galantamiinipreparaat, meetod selle valmistamiseks, seda sisaldav doseerimisvorm ning farmatseutiline pakend
HUP0200309A2 (en) Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression, process for their preparation and pharmaceutical compositions containing them
NO20014835L (no) Fremgangsmate for fremstilling av monodisperse polymerpartikler
IL144501A0 (en) Epothilone derivatives, methods for the preparation thereof and pharmaceutical compositions containing the same
EE9800383A (et) Meetod bioloogiliselt sobivate biodegradeeruvate mikroosakeste valmistamiseks, mikroosakesed ja nendest koosnev materjal, farmatseutiline kompositsioon ning mikroosakeste kasutamine
EP1242112A4 (en) PRODUCTS CONTAINING MEDICINANT SUBSTANCE PARTICLES AND PROCESS FOR PREPARING THE SAME
IL162185A0 (en) Phenylpropionate derivatives, methods for the preparation thereof and pharmaceutical compositions containing the same
EE200300207A (et) Heterotsüklüülalküülpiperidiini derivaadid, nendevalmistamismeetodid ja farmatseutiline kompositsioon
HUP0202781A3 (en) Betha-carboline particulate form, pharmaceutical compositions containing it, their preparations and their use
FR2807038B1 (fr) Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant
PL377854A1 (pl) Farmaceutyczne preparaty donosowe oraz sposoby ich stosowania
AU1080901A (en) Catalyst compositions employing sol particles and methods of using the same
DE60131760D1 (de) Vorrichtung zur verabreichung von physiologisch aktiven wirkstoffen in pulverform
FR2811992B1 (fr) Melanges de polysaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant
IL158297A0 (en) Pharmaceutical compositions containing immune globulin and methods for the preparation thereof
EE04490B1 (et) Ühend, selle valmistamise meetod ning kasutamine meditsiinis
EP1181022A4 (en) MEDICAL COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
EP1476174A4 (en) PHARMACEUTICAL PREPARATION WITH PROPHYLACTIC EFFECTS ON LAMIVUDINE-RELATED REACTIONS AND PHARMACORESISTANCE, AND METHODS OF USING THE SAME
FR2857971B1 (fr) Melanges d'oligosaccharides derives d'heparine, leur preparation et les compositions pharmaceutiques les contenant
HUP0203212A3 (en) Integrin inhibitors, process for preparation thereof, their use preparation of pharmaceutical compositions and the compositions

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20101231